Status:

ACTIVE_NOT_RECRUITING

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Neoplasms

Eligibility:

MALE

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in...

Detailed Description

JNJ-70218902, the investigational drug, has been shown in pre-clinical studies to work by attaching to cancer cells and activating immune cells to kill these cancer cells. This study will be conducted...

Eligibility Criteria

Inclusion

  • Histology: Metastatic castration-resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine features is allowed
  • Measurable or evaluable disease
  • Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
  • If the participant is receiving treatment with gonadotropin-releasing hormone agonists or antagonist analogs (GnRH), this therapy must have been initiated prior to first dose of study drug and must be continued throughout the study
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
  • Adequate organs functions

Exclusion

  • Known brain metastases
  • Concurrent use of any other anticancer treatment or investigational agent for the treatment of advanced disease
  • Toxicities related to prior anticancer treatments have not returned to Grade less than or equal to (\<=) 1 or baseline, except for alopecia and vitiligo
  • Solid organ or bone marrow transplantation
  • Known allergies, hypersensitivity, or intolerance to JNJ-70218902 or its excipients
  • Certain comorbidities

Key Trial Info

Start Date :

July 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2025

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT04397276

Start Date

July 10 2020

End Date

October 30 2025

Last Update

September 12 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

BC Cancer Agency - Vancouver BC

Vancouver, British Columbia, Canada, V5Z 4E6

2

Princess Margaret Hospital

Toronto, Ontario, Canada, M5G 2M9

3

Rambam Medical Center

Haifa, Israel, 31096

4

Sourasky Medical Center

Tel Aviv, Israel, 64239